Is It CIDP or Another Neuropathy? Why a Second Opinion Is Common Before Long-Term Treatment

The envelope arrives with a diagnosis in it, and the word is unfamiliar: chronic inflammatory demyelinating polyneuropathy. A man who has spent four months losing his grip on jar lids and tripping on the top stair reads it twice. Then he reads the next line, the one that mentions infusions, repeated every few weeks, for the foreseeable future.

What surprises many people at this point is the neurologist’s own suggestion: before anything starts, let another specialist look. A CIDP second opinion is not a sign that the first doctor doubts their own skill. It reflects something honest about this condition. There is no blood test that says yes or no. The diagnosis is assembled from a story, an examination, electrical measurements and a few laboratory clues, and at least a dozen other nerve disorders can leave a similar trail.

Because the treatment is long, expensive to the body and sometimes to the spirit, getting the label right at the start is worth the extra weeks.

What does CIDP stand for, and what actually goes wrong in the nerves?

CIDP stands for chronic inflammatory demyelinating polyneuropathy. Each word earns its place. Chronic means the problem has been building for a long time rather than striking in days. Inflammatory means the immune system is driving it. Demyelinating points to the target: myelin, the fatty insulation wrapped around nerve fibers that lets electrical signals travel quickly. Polyneuropathy simply means many peripheral nerves are involved, the nerves outside the brain and spinal cord that reach the arms and legs.

Picture a household extension cord with the plastic sheath nicked in several places. Current still flows, but it leaks, slows and sometimes stops. In CIDP, immune cells and antibodies strip patches of myelin from motor and sensory nerves and from the nerve roots where they leave the spine. Signals from the brain reach the muscles late or not at all, so people notice weakness, often on both sides, in the thighs and shoulders as well as the hands and feet. Sensory fibers suffer too, producing numbness, tingling and a wobbly, uncertain gait, particularly in the dark when the eyes can no longer compensate.

The National Institute of Neurological Disorders and Stroke describes the typical course as symptoms that progress over at least eight weeks, which is the main feature separating CIDP from its short-lived cousin, Guillain-Barré syndrome. Some people worsen steadily, others in steps, and a smaller group relapse and improve in cycles.

Why does the immune system turn on myelin? Researchers do not fully know. Unlike some neuropathies, CIDP is not inherited, not caused by a toxin and not the result of a single infection, although infections may precede a flare. That uncertainty about cause is one reason the diagnosis leans so heavily on pattern recognition.

Why is a CIDP second opinion so common before long-term treatment?

Most medical diagnoses come with an anchor test. A fracture shows on an X-ray; diabetes shows in a glucose number. CIDP has no such anchor. The closest thing is a nerve conduction study, a test in which small electrical pulses are applied to the skin to measure how fast and how completely nerves carry a signal. Demyelination slows that signal in characteristic ways, but the thresholds that separate “slow enough” from “not quite” are drawn by expert consensus, not by nature, and results can sit near the line.

Layered on top is the fact that the treatments are immune-modulating. Corticosteroids, intravenous immunoglobulin and plasma exchange, the three mainstays listed by the National Institute of Neurological Disorders and Stroke, all carry side effects and all tend to be continued or repeated for a long time once started. A clinician who commits a patient to that path wants to be sure the target is really an inflammatory one. Giving an immune treatment to someone whose nerves are being damaged by diabetes or an inherited gene will not help, and may harm.

There is a third, quieter reason. Many people feel somewhat better after any new treatment begins, simply because fatigue fluctuates, attention shifts and hope arrives. A perceived improvement after the first infusion is often taken as confirmation of CIDP, yet neuropathy specialists caution that subjective relief is a weak test. Published reviews of referral-center experience have repeatedly found that a meaningful share of people carrying a CIDP label do not meet consensus criteria when their records are re-examined. The exact proportion varies by study and setting, which is why this article does not quote one figure.

So a second look is not a luxury. For many neurologists it is the standard way to handle a diagnosis that is genuinely hard to make.

CIDP misdiagnosis: which neuropathies are most often mistaken for it?

The honest answer is that CIDP sits at the center of a crowded neighborhood. Peripheral neuropathy, the general term for damage to nerves outside the brain and spinal cord, has well over a hundred recognized causes according to Mayo Clinic, and several of them produce weakness, numbness and slowed nerve conduction that overlap with CIDP.

Diabetic polyneuropathy is the most frequent impostor, simply because diabetes is so common. It usually begins in the toes and climbs slowly, and nerve conduction may be mildly slowed, enough to tempt an inflammatory label when symptoms seem out of proportion to blood sugar control. Hereditary neuropathies, grouped under the name Charcot-Marie-Tooth disease, can show dramatically slowed conduction too; the clue is a lifelong history of high arches, clumsiness in childhood or an affected parent that nobody thought to mention.

Paraprotein-associated neuropathies deserve special attention. A paraprotein is an abnormal antibody produced by a small clone of plasma cells in the bone marrow. Some of these antibodies attack myelin directly and create a picture almost indistinguishable from CIDP, yet they respond differently to treatment and sometimes signal an underlying blood disorder that needs its own evaluation. This is why a blood test for abnormal proteins is part of a thorough workup.

Other lookalikes include neuropathies linked to vitamin B12 deficiency, thyroid disease, kidney failure, certain chemotherapies and alcohol excess; multifocal motor neuropathy, which affects motor nerves only and asymmetrically; and amyloid neuropathy, in which misfolded protein deposits in nerves. Spinal stenosis, a narrowing of the spinal canal that pinches nerve roots, can also mimic the leg weakness.

None of this means a CIDP diagnosis is usually wrong. It means the list of alternatives is long enough that a careful clinician works through it before starting therapy.

CIDP vs GBS: does Guillain-Barré syndrome turn into CIDP?

Guillain-Barré syndrome, usually shortened to GBS, is the acute relative of CIDP. Both are immune attacks on peripheral nerve myelin, both cause symmetric weakness and both are treated with immune therapies. The difference is tempo. The NHS describes GBS as a condition that typically develops over days and worsens for about four weeks before it levels off, often after an infection such as a stomach bug or a chest infection. Most people then recover, sometimes slowly, over months to a year.

CIDP does the opposite. Symptoms keep advancing past the eight-week mark cited by the National Institute of Neurological Disorders and Stroke, or they return after an apparent recovery. That timeline, not the severity, is what tells the two apart.

So does GBS turn into CIDP? In most cases, no. The two are best thought of as separate illnesses that share a mechanism. A small group of people, however, are first labeled GBS because their weakness appeared quickly, only to keep worsening or to relapse repeatedly. Neurologists call this acute-onset CIDP, and the diagnosis is revised once the chronic pattern declares itself. Conversely, GBS can produce a second worsening within a few weeks of treatment, known as a treatment-related fluctuation, which is not CIDP and does not predict it.

This is a classic scenario for a second opinion. Someone treated for GBS who is still declining three months later needs a fresh set of eyes to ask: was this CIDP all along, or is something else explaining the slow recovery, such as severe axonal damage from the original attack, which heals far more slowly than myelin? The answer changes whether ongoing immune therapy makes sense.

Is CIDP a type of MS? Why two demyelinating diseases are not the same

The question is reasonable. Multiple sclerosis is also an immune-mediated demyelinating disease, and people who search the two names together often find overlapping vocabulary: relapses, myelin, immune suppression. Yet CIDP is not a type of MS, and the distinction matters for every part of care.

The dividing line is geography. MS attacks myelin inside the central nervous system, meaning the brain, optic nerves and spinal cord. CIDP attacks myelin in the peripheral nervous system, the nerves that have already left the spine and travel toward the limbs. The myelin in these two territories is made by different cells, oligodendrocytes centrally and Schwann cells peripherally, and it contains different proteins. An immune system that has learned to target one does not automatically target the other.

That is why the symptoms separate so cleanly in practice. MS commonly produces vision loss in one eye, double vision, vertigo, bladder urgency and problems with thinking or speech, because those functions live in the brain and brainstem. CIDP almost never does. Instead it produces loss of reflexes, weakness in the limbs and a particular kind of unsteadiness that comes from the feet no longer sending reliable position signals.

The tests diverge as well. MS is diagnosed largely by brain and spinal cord MRI showing scattered lesions, and the Cleveland Clinic notes that CIDP is diagnosed mainly through nerve conduction studies and spinal fluid analysis, with MRI used chiefly to look at nerve roots. The medications barely overlap. Several MS disease-modifying drugs have no role in CIDP, and intravenous immunoglobulin, a cornerstone of CIDP treatment, is not a standard MS therapy.

Having both conditions is possible but rare. When symptoms seem to involve both territories, that itself is a strong reason for specialist review.

What do the CIDP diagnostic criteria actually ask for?

Neurologists diagnosing CIDP lean on consensus criteria developed by international peripheral nerve societies. The details are technical, but the structure is worth understanding, because it shows why reasonable experts can disagree about a borderline case.

The first requirement is clinical. The classic form, often called typical CIDP, involves weakness in both the proximal muscles, those close to the trunk such as hips and shoulders, and the distal muscles of the hands and feet, on both sides, together with sensory loss and reduced or absent tendon reflexes, progressing for at least eight weeks. Several atypical patterns are also recognized, including forms that are purely sensory, purely distal or confined to one side, and these are harder to pin down.

The second requirement is electrical. Nerve conduction studies must show specific signs of demyelination: slowed conduction velocity, prolonged latencies at the start and end of the nerve, conduction block where a signal fades partway along a nerve, or abnormal temporal dispersion where the signal arrives smeared out rather than crisp. The criteria set numeric thresholds and specify how many nerves must be abnormal. A result that meets the threshold in one nerve but not two may be read differently by two laboratories.

The third tier is supportive evidence. Spinal fluid with raised protein but a normal cell count, a pattern called albuminocytologic dissociation, supports the diagnosis. So does MRI showing thickened, enhancing nerve roots, and so does a clear, objective improvement after immune treatment. A nerve biopsy is now rarely needed.

The criteria also require clinicians to exclude other causes, which is the part most often skipped under time pressure. A second-opinion visit is frequently where that exclusion list gets completed.

Which tests does a second-opinion neurologist usually revisit?

A good second opinion rarely starts from scratch. It starts with the existing file, then fills gaps. The nerve conduction study is almost always reviewed in its raw form rather than as a summary, and often repeated, since technique and limb temperature can shift the numbers. Needle electromyography, or EMG, in which a fine needle records muscle electrical activity, helps separate myelin damage from damage to the nerve fibers themselves, called axonal loss.

Blood work is checked for the lookalikes described earlier: glucose and hemoglobin A1c, vitamin B12, thyroid and kidney function, and a protein electrophoresis with immunofixation to detect a paraprotein. Depending on the pattern, genetic testing for hereditary neuropathy or antibody panels for specific nerve-protein antibodies may be added. If a lumbar puncture, the procedure that samples spinal fluid through a needle in the lower back, has not been done, it is often requested.

The table below summarizes how the common contenders tend to differ. It is a guide to the logic, not a tool for self-diagnosis.

Feature	CIDP	Guillain-Barré syndrome	Diabetic polyneuropathy	Hereditary (Charcot-Marie-Tooth)
Tempo	Progresses beyond 8 weeks or relapses	Peaks within about 4 weeks, then recovers	Very slow, over years	Lifelong, often from childhood
Pattern	Proximal and distal, symmetric	Ascending, symmetric	Feet first, length-dependent	Feet and hands, high arches common
Nerve conduction	Patchy slowing, conduction block	Acute demyelination or axonal	Mild slowing, reduced amplitudes	Uniform, marked slowing
Spinal fluid protein	Often raised	Often raised	Usually normal or mildly raised	Usually normal
Immune treatment	Core of management	Core of acute management	Not indicated	Not indicated

Sources for tempo and pattern: National Institute of Neurological Disorders and Stroke, NHS and Mayo Clinic pages listed in the references.

How is CIDP treated, and why does getting the label right matter so much?

Treatment for CIDP aims to calm the immune attack, allow myelin to repair and, where fibers have survived, restore strength and sensation. Three classes do most of the work, and the National Institute of Neurological Disorders and Stroke lists them side by side: corticosteroids, immunoglobulin therapy and plasma exchange.

Corticosteroids broadly dampen immune activity. Immunoglobulin therapy involves infusing pooled antibodies collected from many healthy donors; the exact mechanism is still debated, but the infused antibodies appear to interfere with the harmful ones and quiet inflammatory signaling. It can be given into a vein or, in some regimens, under the skin. Plasma exchange works mechanically: blood is drawn, the liquid plasma containing the harmful antibodies is removed, and the cells are returned with replacement fluid. For people who do not respond or cannot tolerate these, other immune-suppressing medicines are sometimes considered by specialists.

Each approach has a different burden. Corticosteroids over months can affect bone, blood sugar, weight, mood and sleep. Immunoglobulin requires repeated infusions and can cause headaches, flu-like symptoms and, rarely, clotting or kidney problems. Plasma exchange needs good vein access and often a hospital setting. Which to choose, in what order, and for how long are decisions the treating neurologist makes with the patient, weighing age, other conditions and how quickly things are worsening.

Here is the crux of the second-opinion question. All three treatments act on the immune system, so all three are useless against a neuropathy driven by glucose, a gene or a chemotherapy drug. Worse, the person taking them absorbs the side effects for nothing while the real cause goes untreated. Confirming the inflammatory nature of the disease before committing is therefore not caution for its own sake. It is the single step most likely to make the eventual treatment worthwhile.

Who is usually treated promptly, and who is asked to wait and watch?

Not everyone with a probable CIDP diagnosis is handled the same way, and understanding the logic helps when a second neurologist recommends a different pace from the first.

People whose weakness is progressing quickly, who are losing the ability to climb stairs, grip utensils or walk without support, are usually treated without much delay once the diagnostic picture is reasonably clear. The National Institute of Neurological Disorders and Stroke notes that early treatment is important because nerve fibers themselves can be damaged if demyelination is left unchecked, and axons recover far more slowly than myelin. In this group, the second opinion may happen in parallel with the first treatment course rather than before it.

People at the other end of the spectrum are more often asked to wait. Someone with mild, stable numbness, normal strength, borderline nerve conduction findings and a normal spinal fluid protein may be observed for a defined period, with a repeat examination and repeat electrical studies, before any immune therapy is proposed. The aim is to see whether the condition declares itself as progressive and inflammatory, or whether an alternative explanation emerges. This can feel frustrating, but it protects against years of treatment for a disorder that may never have needed it.

A third group sits in between: people who started treatment elsewhere and are unsure whether it is helping. For them, the second opinion often involves measuring strength, grip and walking in a standardized way, then watching those numbers across a treatment cycle. If objective measures do not move, a supervised pause may be considered. That decision belongs to the treating team and should never be made by stopping a medicine unilaterally.

Pregnancy, kidney disease, heart disease and a history of clots also shape which treatment, if any, is offered first.

What do the weeks after a second opinion usually look like?

The visit itself is only the beginning. Most people leave with one of three outcomes, and each sets a different rhythm for the following weeks.

If the second specialist agrees with the diagnosis and the plan, the most common sequence is a baseline assessment, treatment start, then a review after a full course. Clinicians generally judge CIDP treatment response over weeks rather than days, because myelin repair is slow and the first signs of improvement are often subtle: a stair that feels easier, a bottle cap that yields. The treating neurologist will set the review interval; it varies with the therapy chosen.

If the specialist is unsure, expect additional testing. This may mean a repeat nerve conduction study on a different day, a lumbar puncture, extra blood tests, or imaging of the nerve roots. Lumbar puncture results typically return within days; genetic and specialized antibody tests can take considerably longer. People in this group often describe the waiting as the hardest part, and it is reasonable to ask the clinic how to reach them if symptoms change in the meantime.

If the specialist proposes a different diagnosis, the path diverges entirely. A hereditary neuropathy leads to genetic counseling and physical therapy rather than infusions. A paraprotein leads to a hematology referral. Diabetes-related nerve damage leads back to metabolic care.

Whatever the outcome, physical and occupational therapy usually begin or continue, because maintaining range of motion, balance and safe walking helps regardless of the final label. Many people also benefit from a simple symptom diary noting strength, falls and fatigue, which gives both neurologists something objective to compare at the next review.

What people often get wrong about CIDP

Misconceptions cluster around this diagnosis, partly because it is rare and partly because the name invites comparison with better-known diseases. A few deserve correcting.

The first is that a second opinion means the first neurologist got it wrong. Usually it means the opposite: a careful clinician recognizing that the diagnosis is probabilistic and asking for confirmation before a long commitment. Agreement between two specialists is a common and reassuring outcome.

The second is that feeling better after the first treatment proves the diagnosis. Fatigue and pain fluctuate in every neuropathy, and expectation shapes how people feel. Specialists place far more weight on measured changes, such as grip strength, timed walking or standardized disability scores, than on a general sense of improvement.

The third is that CIDP is a form of multiple sclerosis or a sign that MS will follow. As explained above, the two diseases affect different nervous systems and are managed with largely different medicines.

The fourth is that nerve conduction studies are either normal or abnormal. In reality they produce numbers that fall on a spectrum, with thresholds set by consensus. Two competent laboratories can read the same borderline tracing differently, which is precisely why raw data travel with the patient to a second opinion.

The fifth is that CIDP always worsens relentlessly. The Cleveland Clinic describes a condition that can be progressive, stepwise or relapsing, and many people experience long periods of stability on treatment. The sixth is the mirror image: that a few good months mean treatment can simply be dropped. Relapses after stopping therapy are well recognized, so any change should be planned and monitored with the treating team.

Finally, CIDP is not caused by anything the patient did. No diet, posture or lifestyle choice is known to trigger it.

Questions to ask your care team before committing to long-term treatment

A second-opinion appointment is more useful when the questions are specific. These are the ones neuropathy specialists most often wish patients would ask, phrased so that the answers can be compared between two clinicians.

• Which of the consensus criteria for CIDP do I meet, and which are borderline or missing?
• How many nerves showed demyelinating features on my conduction study, and were my limbs warm enough during testing for the numbers to be reliable?
• Have the main alternative causes been excluded, specifically diabetes, vitamin B12 deficiency, thyroid disease, a paraprotein and hereditary neuropathy?
• Is a lumbar puncture or MRI of the nerve roots likely to change the decision in my case?
• If treatment starts, what objective measures will you use to decide whether it is working, and when will you reassess?
• What is the plan if the first treatment does not produce measurable improvement?
• How will we know, later on, whether the disease has gone quiet enough to consider reducing treatment under supervision?
• Which side effects should I report straight away, and which can wait for the next visit?
• Would physical or occupational therapy help now, regardless of the final diagnosis?
• Is there anything in my history, such as a childhood foot shape, an affected relative or an earlier episode of weakness, that you would like to know more about?

Bring copies of the original nerve conduction tracings, not just the written report, along with blood results and any spinal fluid findings. If two opinions differ, ask each clinician to explain the specific finding that drives their view. Disagreements in CIDP usually come down to one or two data points, and naming them turns an uncomfortable standoff into a solvable problem that the treating team can resolve with a targeted test or a period of observation.

When to call your doctor: red-flag signs that should not wait

Most of the uncertainty around CIDP plays out over weeks, which is manageable. A few developments are different: they signal that nerve damage is accelerating, that breathing or swallowing is involved, or that a treatment complication may be unfolding. These need a same-day call, and in some cases emergency care.

Contact your doctor or seek urgent help if weakness is clearly worse over a matter of days rather than weeks, especially if you have gone from walking independently to needing support, or can no longer rise from a chair without using your arms. Any difficulty swallowing, choking on liquids, change in voice or trouble taking a deep breath is an emergency, because the nerves that drive the diaphragm and throat can be affected in rapidly progressive inflammatory neuropathy, as the NHS warns for Guillain-Barré syndrome. New double vision or facial drooping deserves the same urgency.

Watch also for signs that point away from the limbs: new problems controlling bladder or bowel, severe back pain with leg weakness, or weakness confined to one side of the body. These suggest the spinal cord or brain rather than peripheral nerves and need prompt reassessment.

If you are already on treatment, call about a severe or unusual headache after an immunoglobulin infusion, a swollen or painful calf, chest pain or sudden breathlessness, which can indicate a clot; fever that does not settle; marked thirst and frequent urination on corticosteroids; or dark urine with reduced output. Falls with head injury, even if you feel fine, should be reported.

If none of this applies but something simply feels different, it is still reasonable to call. Describing a change early gives the treating team the option of bringing forward a review, and nothing in this article replaces their judgment.

How to prepare for a CIDP second opinion so the visit actually settles the question

A second opinion succeeds or fails on the quality of the information that arrives with you. The most valuable item is the original nerve conduction and EMG data, including the tracings and the temperature recorded at the time. Written summaries lose detail, and a borderline result can only be re-read from the numbers themselves.

Next comes a timeline. Write down, as precisely as memory allows, when the first symptom appeared, what it was, how it spread and whether there were periods of improvement. Note any infection or vaccination in the weeks before onset, not because these prove anything, but because they help the clinician place the illness on the acute-to-chronic spectrum described by the National Institute of Neurological Disorders and Stroke. If you have been treated, record what was given, roughly when, and what changed in measurable terms: stairs climbed, distance walked, objects lifted.

Family history matters more than people expect. Ask relatives about high arches, hammer toes, lifelong clumsiness, early use of walking aids or a neuropathy diagnosis of any kind. A single affected cousin can redirect the entire workup toward hereditary testing.

Gather the full list of medicines and supplements, including past chemotherapy or long courses of antibiotics, and recent results for glucose, B12, thyroid, kidney function and protein electrophoresis if they exist. Bring a list of your own questions, drawn from the section above, and consider bringing someone to take notes.

Ask in advance whether the appointment is a records review, a full re-examination or both, and whether repeat electrical studies will be done on the day. Clarify how the second neurologist will communicate with the first; in most settings the two share findings directly, and the final decision about treatment remains with the team that will deliver it.

Approached this way, a CIDP second opinion stops being a detour and becomes the foundation for everything that follows.

Frequently asked questions

What does CIDP stand for?

CIDP stands for chronic inflammatory demyelinating polyneuropathy. It is a rare condition in which the immune system attacks myelin, the insulating sheath around peripheral nerves, causing progressive or relapsing weakness and numbness in the limbs. Chronic refers to symptoms that advance for at least eight weeks, which distinguishes it from the acute form, Guillain-Barré syndrome.

Why would my neurologist suggest a CIDP second opinion if they already made the diagnosis?

Because the diagnosis depends on interpreting borderline electrical and clinical findings rather than a definitive test, and the treatment is long-term immune therapy with real side effects. Asking a colleague to confirm the pattern before committing is standard practice among peripheral nerve specialists, and agreement between the two is a common outcome rather than a sign of error.

Does GBS turn into CIDP?

Usually not. Guillain-Barré syndrome and CIDP are separate illnesses sharing an immune mechanism. A small number of people initially labeled GBS keep worsening beyond eight weeks or relapse repeatedly, and their diagnosis is then revised to acute-onset CIDP. A brief second dip within weeks of GBS treatment, called a treatment-related fluctuation, is not CIDP and does not predict it.

Is CIDP a type of MS?

No. Multiple sclerosis damages myelin in the brain, optic nerves and spinal cord, while CIDP damages myelin in the peripheral nerves of the arms and legs. The myelin is made by different cells, the symptoms differ, MS is diagnosed mainly by MRI and CIDP mainly by nerve conduction studies, and the medicines used for one generally have no role in the other.

How common is CIDP misdiagnosis?

Precise figures vary by study and setting, so a single percentage would be misleading. Published reviews from specialist referral centers consistently report that a meaningful share of people who arrive with a CIDP label do not meet consensus criteria on re-examination, often because borderline nerve conduction results were over-read or alternative causes such as diabetes or hereditary neuropathy were not excluded.

What are the CIDP diagnostic criteria based on?

International consensus criteria combine three elements: a clinical pattern of symmetric proximal and distal weakness with sensory loss and reduced reflexes progressing for at least eight weeks; nerve conduction findings of demyelination such as slowed velocity, conduction block or dispersion in a specified number of nerves; and supportive evidence including raised spinal fluid protein, nerve root MRI changes or objective treatment response, after other causes are excluded.

Does CIDP qualify for disability?

It can, depending on how much it limits function and on the rules of the program involved, which differ by country and employer. Eligibility is generally assessed on documented impairment such as walking ability, hand function and fatigue rather than on the diagnosis alone. Your treating team can provide the clinical documentation; a social worker or benefits advisor can explain the specific process.

Can CIDP be mistaken for diabetic neuropathy, and how do doctors tell them apart?

Yes, this is one of the most frequent sources of confusion. Diabetic neuropathy usually begins in the toes and climbs slowly over years with mild conduction slowing, while CIDP typically involves proximal muscles as well, progresses over weeks to months and shows patchy demyelination with conduction block. Spinal fluid protein and blood sugar history help, and a second opinion often focuses on exactly this distinction.

What should I bring to a CIDP second opinion appointment?

Bring the original nerve conduction and EMG tracings rather than just the report, a written timeline of when symptoms began and how they spread, results of blood tests for glucose, B12, thyroid, kidney function and protein electrophoresis, any spinal fluid results, a complete medicine list including past chemotherapy, and a family history of foot shape, clumsiness or neuropathy. A list of questions and a companion to take notes also help.

How long does it take to know if CIDP treatment is working?

Response is usually judged over weeks rather than days, because myelin repairs slowly and early gains are subtle. The treating neurologist sets a review point after a full treatment course and compares objective measures such as grip strength and timed walking against baseline. If those numbers do not improve, the team may reconsider the diagnosis or the treatment choice before continuing long term.

References

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), National Institute of Neurological Disorders and Stroke
• Chronic inflammatory polyneuropathy, MedlinePlus Medical Encyclopedia
• Guillain-Barré syndrome, NHS

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.